Farnesoid X Receptor (FXR) Agonist – Pipeline Review, 2019

Farnesoid X Receptor (FXR) agonist is a member of the nuclear receptor superfamily. Nuclear receptors are ligand activating transcription factors which modulate significant biological functions. FXR agonist with bile acids as a natural ligand regulates bile acid synthesis, as well as various aspects of lipid and glucose metabolism involved in pathologies of human diseases like diabetes and chronic liver diseases. Thus, FXR agonist acts as a promising pharmacological target in treatment against these diseases.

Currently, FXR is used as a target for drug therapies against metabolic dysregulation in obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Obeticholic acid is used in the treatment of liver diseases by increasing the bile flow from the liver and suppressing the bile production in the liver. Additionally, Cholic acid and Turofexorate Isopropyl are also used to activate FXR in the regulation of bile acid synthesis.

Pharmaceutical companies, along with various research institutes, have been focusing on studying and developing new treatment options by employing Farnesoid X Receptor (FXR) agonist. For instance; EYP001a which is being studied by Enyo Pharma is currently in phase-1 clinical trials for the study of safety, tolerability, and efficacy of EYP001a, a synthetic FXR agonist for the treatment of hepatitis B.

At present, around 60% of the pipeline candidates for Farnesoid X Receptor (FXR) agonist are in the phase-1 clinical study. Majority of the Farnesoid X Receptor (FXR) agonist studies are sponsored by industry.

Report Description

The report on ‘Farnesoid X Receptor (FXR) Agonist – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Farnesoid X Receptor (FXR) Agonist. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Farnesoid X Receptor (FXR) Agonist.

The report on ‘Farnesoid X Receptor (FXR) Agonist – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Farnesoid X Receptor (FXR) Agonist
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Farnesoid X Receptor (FXR) Agonist
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary